Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

rm using the effective interest method.

The foreign exchange gains and losses were nominal for each of Q1/08 and Q1/07.

Liquidity and Capital Resources

As of July 31, 2007, the Company had cash, cash equivalents and short-term investments of $12.8 million (April 30, 2007: $15.3 million) and the Company's net working capital was $12.1 million (April 30, 2007: $14.6 million). The $2.5 million decrease in net working capital from April 30, 2007 is primarily attributable to the cash loss of $2.4 million (loss excluding non-cash expenses: amortization, stock-based compensation and accretion of the convertible royalty participation units) for the three months ended July 31, 2007.

MIGENIX believes that its funds on hand at July 31, 2007, together with ongoing cost containment measures and expected interest income, are sufficient to provide for operations into the third quarter of calendar 2008 before funds received, if any, from existing or new license agreements, the exercise of warrants and options and future financing activities. The Company will continue advancing its highest priority programs while operating within an annual burn rate of $11 million to $13 million. The magnitude of spending in the Company's development programs will be dependent on the licensing status of the celgosivir program and results in the programs, and we may need to increase or decrease our annual burn rate in response to such results. MIGENIX is likely to need to raise additional funds in support of its operations and there is no assurance that such funds can be obtained

Outstanding Shares

There are currently 94,463,806 (July 31, 2007: 94,463,806; April 30, 2007: 94,237,205) common shares outstanding; 29,465 convertible royalty participation units (July 31, 2007 and April 30, 2007: 29,465); and 9,250,000 (July 31, 2007: 9,250,000; April 30, 2007: 9,350,000) preferred shares outstanding. In May 2007 the Company converted 50,000 Series A and 50,000 Series B
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:6/30/2015)... 1, 2015 R-Japan Co.,Ltd. obtained the license of ... Regenerative Medicine from the Ministry of Health, Labour and Welfare ... The fact that R- Japan ... auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May ... to provide stem cell manufacturing service to medical institutions. As ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... a webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based ... energy. Touted as 'the wonder material of the 21st Century' by the ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  Today, Americord ... the U.S., announced Andrew Horne , a partner at ... Advisory Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... appointment to Americord,s Advisory Board," says Martin Smithmyer , ... experience in his legal career that will assist Americord,s growth ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... Physicians (ACCP) Guidelines Will Increase ... Use of Trellis(R) Peripheral Infusion System, NORTHBROOK, Ill., ... has published new evidence-based clinical guidelines for,physicians that for ... acute iliofemoral deep vein thrombosis (DVT) in,conjunction with anticoagulation ...
... local officials have taken steps to begin monitoring the ... a cutting-edge technology that has yet to be regulated ... the Cambridge (Mass.) Public Health Department recommended to the ... a better understanding of the nature and extent of ...
... customer ... and operational efficiency, BOSTON, July 28 AMICAS, Inc. ... and information management,solutions, today announced a new partnership with Arcadia ... (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ), For more than 40 ...
Cached Biology Technology:Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT 2Local officials move toward monitoring nanotechnologies 2Local officials move toward monitoring nanotechnologies 3Arcadia Radiology Medical Group Chooses AMICAS 2Arcadia Radiology Medical Group Chooses AMICAS 3
(Date:6/17/2015)... , and HILDEN, Germany , June ... QGEN ; Frankfurt Prime Standard: QIA) today launched new Investigator ... in forensic laboratories in the United States ... to simultaneously analyze multiple key genomic markers (short tandem repeats ... Quality Sensor to evaluate the quality of DNA in ...
(Date:6/16/2015)... June 16, 2015  With the increasing number and ... a top concern. The recent compromise of Federal ... for strong authentication within government agencies. HYPR ... one-time password (OTP) authenticator, has been submitted for testing ... Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... 15, 2015 A new report [ ... the majority of US consumers using mobile banking applications want ... as fingerprint and voiceprint, instead of having to prove who ... Telstra,s " Mobile Identity   -   The Fusion of ... smartphones now the primary channel used by Gen X and ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... just a single island in the remote South Pacific, is ... also one of the oldest flowering plants, having branched off ... Indiana University, with the U.S. Department of Energy Joint Genome ... Research for Development in New Caledonia, have determined a remarkable ...
... Ven, Department of Molecular Biology and Genetics and the ... microRNA-128 just published in Science . In the ... amount of microRNA-128 in specific neurons that react to ... in these neurons in neonatal mice, it results in ...
... a cloudless day in Dangriga, a coastal city in southern ... wall of their sun-strewn lab is lined with the usual ... tubes. Swathed in purple gloves, they measure samples, mix gels ... usual class this is not. It is part of ...
Cached Biology News:A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3New research provides insight into epilepsy 2Beyond Mendel 2Beyond Mendel 3Beyond Mendel 4
... GEMINI is Tecan's pipetting software for life ... Freedom and the GENESIS WORKSTATION instruments including ... software enables the user the simple graphical ... pipetting scripts. With the powerful scripting language ...
... a revolutionary new application for DNA ... novel interface, Expression makes complex computational ... Expression uses the very latest computing ... the way sequences are analysed. Features ...
...
... Partek Genomics Solution is a ... interactive data visualization specifically designed to ... Designed for high-dimensional genomic studies containing ... is fast, memory efficient and will ...
Biology Products: